Antiphospholipid Syndrome: Not All Antibodies Are Created Equal
Nicola Pozzi, Associate Professor of Thrombosis and Hemostasis and Autoimmunity at Saint Louis University School of Medicine, shared a post on LinkedIn:
”Antiphospholipid Syndrome (APS) isn’t a one-size-fits-all disease—and neither are antiphospholipid antibodies.
In our latest work, led by Suresh Kumar, we advance understanding of the molecular complexity behind pathogenic antibodies targeting β2GPI and, in doing so, we introduce new concepts and tools that may help achieve more personalized diagnostic strategies and accelerate the development of neutralization approaches.
Our goal of building an Antiphospholipid Antibody Atlas to fight APS continues… Just keep watching APS…Just keep watching…”
For more information
Find More Posts on Hemostasis Today.
-
Sep 18, 2026, 17:48Ronak H. Mistry: Updated ASH Guidelines Bring New Focus to Iron Deficiency
-
Sep 18, 2026, 17:32Hassan Kawtharany: New Ferritin Cutoffs for the Diagnosis of Iron Deficiency With or Without Anemia
-
Sep 18, 2026, 17:20Abhishek G P: GAVE as an Important Cause of Chronic Gastrointestinal Blood Loss
-
Sep 18, 2026, 17:08Irem Karaman Sebin: ASH 2026 Changes a Key Concept in Iron Deficiency
-
Sep 18, 2026, 16:51Adarsh Krishnan Sundara Rajan: Is VTE the Most Underdiagnosed Critical Threat in Modern Healthcare?
-
Sep 18, 2026, 16:19CRISPR and Hemophilia: The Next Frontier of In Vivo Gene Editing
-
Sep 18, 2026, 16:13Christian Irsara: PF4 Immunothrombosis Following Natural Adenovirus Infection
-
Sep 18, 2026, 16:10Leo Nicolai։ The Spleen Emerges as a Key Regulator of Thromboinflammation
-
Sep 18, 2026, 16:05Targeting Factor XI to Reduce Thrombosis Without Compromising Hemostasis – ISTH